Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

220
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
220
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

220
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
220
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

265
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
265
What is Metabolism?00:52

What is Metabolism?

131.4K
Overview
131.4K
Hepatic Portal System01:21

Hepatic Portal System

5.6K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.6K
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

13.9K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
13.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expression of insulin-like growth factor-I and insulin-like growth factor binding proteins during thioacetamide-induced liver cirrhosis in rats.

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society·2005
Same author

Postnatal development of hepatocellular apolipoprotein B assembly and secretion in the rat.

Journal of lipid research·2001
Same author

Effect of bile acids on the proliferative activity and apoptosis of rat hepatocytes.

Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie·2001
Same author

Separation of the intracellular secretory compartment of rat liver and isolated rat hepatocytes in a single step using self-generating gradients of iodixanol.

Analytical biochemistry·1999
Same author

Chronic liver injury alters basal and stimulated nitric oxide production and 3H-thymidine incorporation in cultured sinusoidal endothelial cells from rats.

Journal of hepatology·1999
Same author

Expression of tenascin, fibronectin, and laminin in rat liver fibrogenesis--a comparative immunohistochemical study with two models of liver injury.

Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie·1998

Related Experiment Video

Updated: Jan 25, 2026

High-Density Lipoprotein-Specific Phospholipid Efflux Assay
07:08

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

398

Hepatic lipoprotein metabolism

R Dargel

    Przeglad Lekarski
    |January 1, 1987
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
    06:47

    Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

    Published on: January 28, 2021

    12.4K
    Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification
    10:39

    Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification

    Published on: November 28, 2016

    11.8K

    Related Experiment Videos

    Last Updated: Jan 25, 2026

    High-Density Lipoprotein-Specific Phospholipid Efflux Assay
    07:08

    High-Density Lipoprotein-Specific Phospholipid Efflux Assay

    Published on: September 30, 2025

    398
    Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
    06:47

    Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

    Published on: January 28, 2021

    12.4K
    Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification
    10:39

    Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification

    Published on: November 28, 2016

    11.8K